

Eviti Imaging: Cervical Cancer

Version: 1.0

Effective Date: 1/1/2026



Please note the following:

CPT Copyright 2026 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

All information provided by the NCCN is "Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) © 2026 National Comprehensive Cancer Network. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org."

For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Please refer to the CMS website at <http://www.cms.gov> for additional information.

For Medicaid members/enrollees, circumstances when state Medicaid coverage provisions conflict with the coverage provisions within this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Cervical Cancer Imaging

Discussion

This imaging guideline provides a standardized framework for the use of diagnostic and surveillance imaging in the management of common adult malignancies, specifically cervical cancer. The goal is to ensure timely, evidence-based imaging that supports accurate staging, treatment planning, response assessment, and post-treatment surveillance.

Guiding Principles

- Follow evidence-based practices from major guidelines (e.g., NCCN, ESMO, ACR Appropriateness Criteria)
- Ensure imaging aligns with the clinical context and stage of disease
- Minimization of unnecessary radiation exposure
- Promote timely and cost-effective imaging utilization
- Incorporate multidisciplinary collaboration in imaging decisions

Imaging Guidelines

This guideline applies to the following patients:

1. At least 18 years of age with confirmed or suspected diagnoses of cervical cancer; AND
2. All phases of oncologic care, including one of the following:
 - a) Initial staging
 - b) Treatment response evaluation
 - c) Post-treatment surveillance
 - d) Detection of recurrence or progression; AND
3. All imaging modalities used in oncology care, including but not limited to the following:
 - a) Computed Tomography (CT) (neck, chest, abdomen, pelvis, neck, or site-specific)
 - b) Magnetic Resonance Imaging (MRI) (including site-specific protocols such as pelvis MRI, brain MRI, liver MRI)
 - c) Fluorodeoxyglucose Positron Emission Tomography/CT (FDG-PET/CT)
 - d) PET/MRI
 - e) Somatostatin Receptor PET/CT (SSTR-PET/CT)
 - f) Nuclear Medicine (e.g., bone scan, PSMA PET)
 - g) Single Photon Emission Computed Tomography/CT (SPECT/CT) (e.g., octreotide SPECT/CT for neuroendocrine tumors)

Notes:

1. The concurrent utilization of multiple advanced imaging modalities—such as PET/CT and MRI—is not routinely warranted and should be considered only when each modality is expected to provide distinct and clinically relevant information that will directly impact patient management. The selection of the most appropriate imaging study should be individualized, taking into account tumor type, clinical presentation, prior imaging, and other patient-specific factors. Imaging requests will be evaluated on a case-by-case basis to ensure clinical necessity, appropriateness, and the potential to influence therapeutic decision-making.

- When PET imaging is clinically indicated, the appropriate radiotracer should be selected based on tumor type and clinical scenario.

Cervical Cancer Imaging

Imaging in cervical cancer is essential for accurate staging, treatment planning, and post-therapy surveillance. The choice of modality depends on clinical stage, symptomatology, and treatment intent.

Cross-sectional imaging is critical for assessing tumor extent, nodal involvement, and distant metastases. MRI provides superior pelvic soft tissue delineation, while PET/CT is valuable for evaluating nodal and distant disease, particularly in locally advanced cases.

Cervical Cancer Recommendations			
Clinical Scenario	Recommended Modality	Frequency/Timing	Purpose/Notes
Initial Staging - IB1 and Higher	MRI pelvis	Once at diagnosis	Preferred for local staging—defines tumor size, parametrial, and vaginal extension
	CT chest/abdomen/pelvis or PET/CT	Once at diagnosis Once at diagnosis (Stage IB1 or higher)	Evaluate lymph nodes and distant metastases (lung, liver, para-aortic) Recommended for detection of nodal/distant metastases; may replace CT for systemic staging PET/CT (preferred)
	MRI brain (if small cell neuroendocrine)	Once at diagnosis	
Treatment Monitoring - Locally Advanced, Recurrent, and Stage IV	CT chest/abdomen/pelvis	Every 2-3 months	NCCN does not specifically note a duration for imaging interval although imaging should be primarily symptom-driven
	FDG-PET/CT	Every 2-3 months	PET CT when clinically indicated due to inconclusive

			findings on conventional imaging
	MRI pelvis	Every 2-3 months	
Surveillance - Post Treatment Evaluation After Fertility-Sparing Surgery	MRI pelvis	At 6 months then annually for 2-3 years	Assesses tumor size and stromal invasion; essential for radical trachelectomy consideration
Surveillance - Post Treatment Evaluation Stages IB3-IV	FDG-PET/CT	At 3–6 months post-therapy	PET preferred. If PET finding indeterminate then repeat at 3 months
	CT pelvis/abdomen ± chest	At 3–6 months post-therapy	May also consider imaging in patients with high risk features or required radiation or chemoradiation
	MRI pelvis	At 3–6 months post-therapy	
Suspected Recurrence	FDG-PET/CT	As clinically indicated	Most sensitive for detecting recurrent/metastatic disease. Guides biopsy or therapy
	CT pelvis/abdomen ± chest	As clinically indicated	
	MRI pelvis	As clinically indicated	Evaluate local recurrence, especially in previously irradiated pelvis

Notes:

1. PET/CT is preferred over CT for advanced disease (≥IB3 or node-positive).
2. MRI with and without contrast is the gold standard for local assessment of cervical tumor and parametrial invasion.
3. Imaging is not routinely recommended for surveillance unless clinically indicated.
4. Recurrence patterns often include pelvic sidewall, para-aortic nodes, lungs, and liver—use imaging tailored to suspected sites.
5. For fertility-sparing management, MRI ensures accurate measurement of tumor <2 cm and absence of parametrial invasion.¹

Revision and Review History

No.	Description	Date
1	Original Effective Date:	1/1/2026
2	Policy Annual Review Dates:	
3	Department Owner:	Medical Affairs
4	NH Advisory Committee Approval Dates:	
5	Revision Changes:	

References

¹ National Comprehensive Cancer Network Guidelines: Cervical Cancer. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed December 15, 2025.